Affiris

Risk score

57
Large logo of Affiris

Headquarters

Flag of AustriaAustria

Since our establishment in 2003, we have been dedicated to our goal of utilizing the immune system to detect and combat proteins fundamental to the progression and development of neurodegenerative conditions. Our primary objective is to enhance the quality of life for patients afflicted by neurodegenerative diseases, by prioritizing the underlying cause rather than addressing symptoms: a principle influenced by the profound impact of vaccines on global health and society. We possess a diverse range of immunotherapy prospects currently undergoing clinical trials or in the preclinical phase for various neurodegenerative disorders.